Josh Mandel-Brehm - 10 Oct 2024 Form 3 Insider Report for Camp4 Therapeutics Corp (CAMP)

Role
Chief Executive Officer, Director
Signature
By: /s/ Thomas Danielski, as Attorney-in-Fact
Issuer symbol
CAMP
Transactions as of
10 Oct 2024
Net transactions value
$0
Form type
3
Filing time
10 Oct 2024, 21:06:23 UTC
Previous filing
07 Oct 2024
Next filing
15 Oct 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CAMP Common Stock 271,752 10 Oct 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CAMP Series B Preferred Stock 10 Oct 2024 Common Stock 605 Direct F1
holding CAMP Stock Option (Right to Buy) 10 Oct 2024 Common Stock 25,048 $2.12 Direct F2
holding CAMP Stock Option (Right to Buy) 10 Oct 2024 Common Stock 2,268 $2.12 Direct F2
holding CAMP Stock Option (Right to Buy) 10 Oct 2024 Common Stock 30,719 $2.12 Direct F2
holding CAMP Stock Option (Right to Buy) 10 Oct 2024 Common Stock 2,835 $2.12 Direct F2
holding CAMP Stock Option (Right to Buy) 10 Oct 2024 Common Stock 1,417 $2.12 Direct F2
holding CAMP Stock Option (Right to Buy) 10 Oct 2024 Common Stock 66,869 $5.50 Direct F3
holding CAMP Stock Option (Right to Buy) 10 Oct 2024 Common Stock 341,687 $8.41 Direct F4
holding CAMP Stock Option (Right to Buy) 10 Oct 2024 Common Stock 44,579 $9.08 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Preferred Stock is convertible into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a 11.2158-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Preferred Stock has no expiration date.
F2 This option is fully vested and exercisable as of the date hereof.
F3 This option had a vesting start date of March 1, 2022 and vests in equal monthly installments over 48 months, beginning on the one-month anniversary of the vesting start date.
F4 This option had a vesting start date of September 1, 2022 and vests in equal monthly installments over 48 months, beginning on the one-month anniversary of the vesting start date.
F5 This option had a vesting start date of March 7, 2024 and vests in equal monthly installments over 48 months, beginning on the one-month anniversary of the vesting start date.

Remarks:

Exhibit 24 - Power of Attorney